WILMINGTON, Del., July 25, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:

• Do you, or did you, own shares of Chiasma, Inc. (NASDAQ:CHMA)?
  
  
• Did you purchase your shares pursuant and/or traceable to the July 15, 2015 Registration Statement and Prospectus, or between July 15, 2015 and April 17, 2016, inclusive?
  
  
• Did you lose money in your investment?

Rigrodsky & Long, P.A. reminds shareholders of Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ:CHMA) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.  A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of Chiasma pursuant and/or traceable to the July 15, 2015 Registration Statement and Prospectus, or between the period of July 15, 2015 and April 17, 2016, inclusive (the “Class Period”) alleging violations of the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.  Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) Chiasma’s Phase 3 clinical trial methodology for Mycapssa, its lead product candidate, was not sufficient to demonstrate efficacy and secure U.S. Food and Drug Administration (“FDA”) approval; (2) Chiasma’s supervision of its suppliers was not sufficient to prevent deficiencies that would delay FDA approval of Mycapssa; and (3) as a result of the foregoing, Chiasma’s public statements were materially false and misleading at all relevant times.  As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2016.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

If you purchased shares of Chiasma pursuant and/or traceable to the July 15, 2015 Registration Statement and Prospectus, or between the period of July 15, 2015 and April 17, 2016, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to info@rl-legal.com; or at: http://rigrodskylong.com/investigations/chiasma-inc-chma.    
                            
Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT: 

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rl-legal.com 
http://www.rigrodskylong.com